Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
Do you feel that 5 years of follow-up is adequate to change management?
If you will defer, how will your approach differ for triple-negative vs. ER/PR-negative, but HER2-positive patients?
1 Answer
Mednet Member
Radiation Oncology · Methodist Dallas Medical Center
Answered on
I will await more data with subgroup analysis prior to changing my practice pattern.
Join for free or sign in to see the full answer